文献速递肝病

系统综述与Meta分析:利福昔明用于自发性细菌性腹膜炎的预防

Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis.
PubMed 文献 · Aliment Pharmacol Ther · 2017-10-09

该系统综述与Meta分析评估利福昔明对肝硬化腹水患者自发性细菌性腹膜炎(SBP)的一级和二级预防效果。与全身抗生素相比,利福昔明组SBP的合并OR为0.45(95%CI 0.16-1.27;P=.13),敏感性分析后增强(OR 0.38,95%CI 0.19-0.76,P=.01);与无抗生素相比,OR为0.34(95%CI 0.11-0.99;P<.05)。作者认为利福昔明可能有效。

要点

  • 与全身抗生素相比,利福昔明组SBP的OR为0.45(95%CI 0.16-1.27;P=.13),敏感性分析OR为0.38(95%CI 0.19-0.76;P=.01)。
  • 与无抗生素相比,利福昔明组SBP的OR为0.34(95%CI 0.11-0.99;P<.05)。
  • 亚组分析中,一级预防与无抗生素相比SBP风险降低47%,二级预防与全身抗生素相比降低74%。

核心结论

  • 与全身吸收性抗生素和安慰剂相比,利福昔明可能有效预防肝硬化腹水患者的SBP。

研究设计与样本

  • 系统综述与Meta分析,检索5个数据库,纳入比较利福昔明与SBP相关性的研究。
  • 进行两项Meta分析:利福昔明对比全身抗生素,以及利福昔明对比无抗生素。
  • 采用随机效应模型计算合并估计值和95%置信区间(CI)。

主要发现

  • 利福昔明对比全身抗生素:5项研究共555例患者(利福昔明295例,全身抗生素260例),SBP的合并OR为0.45(95%CI 0.16-1.27;P=.13),敏感性分析后OR为0.38(95%CI 0.19-0.76;P=.01)。
  • 利福昔明对比无抗生素:5项研究共784例患者(利福昔明186例,无抗生素598例),SBP的OR为0.34(95%CI 0.11-0.99;P<.05)。
  • 亚组分析:一级预防中,与无抗生素相比,利福昔明使SBP风险降低47%;二级预防中,与全身抗生素相比降低74%。

临床怎么用

  • 原文结论指出,与全身吸收性抗生素和安慰剂相比,利福昔明可能有效预防肝硬化腹水患者的SBP。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The primary and secondary prevention of spontaneous bacterial peritonitis (SBP) is recommended in high-risk patients with cirrhosis. Several studies evaluating the efficacy of rifaximin for SBP prophylaxis have yielded conflicting results. Rifaximin has the potential advantage of preventing bacterial overgrowth and translocation without the systemic side effects of broad-spectrum antibiotics. AIM: To evaluate the efficacy of rifaximin in the primary and secondary prevention of SBP. METHODS: A literature search using five databases was performed to identify studies on the association between rifaximin and SBP. We performed two meta-analyses: (1) rifaximin compared to systemic antibiotics and (2) rifaximin compared to no antibiotics. Random-effect modelling was conducted to determine overall pooled estimates and 95% confidence intervals (CIs). RESULTS: Five studies with 555 patients (295 rifaximin, 260 systemic antibiotics) compared rifaximin with systemic antibiotics. The pooled odds ratio (OR) for SBP was 0.45 (95% CI 0.16-1.27; P = .13) in patients receiving rifaximin and strengthened on sensitivity analysis (OR 0.38, 95% CI 0.19-0.76, P = .01). In the analysis comparing rifaximin with no antibiotics, there were five studies with 784 patients (186 rifaximin, 598 no antibiotics). The OR for SBP was 0.34 (95% CI 0.11-0.99; P < .05) in patients receiving rifaximin. In subgroup analysis, rifaximin reduced the risk of SBP by 47% compared to no antibiotics for primary prophylaxis and by 74% compared to systemic antibiotics for secondary prophylaxis. CONCLUSION: Rifaximin may be effective in preventing SBP in patients with cirrhosis and ascites compared to systemically absorbed antibiotics and compared to placebo.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Goel A, Rahim U, Nguyen LH, et al. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharmacol Ther. 2017. PMID: 28994123. doi:10.1111/apt.14361

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。